Skip to main content

Advertisement

Log in

Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literature

  • Case Report
  • Published:
CEN Case Reports Aims and scope Submit manuscript

Abstract

A 47-year-old Caucasian man developed mild diarrhoea associated with more than 10 kg weight loss, severe fatigue and anaemia. Endoscopy demonstrated deposits of AA amyloid within the gastrointestinal tract. He had heavy proteinuria with a serum albumin of 15 g/L consistent with systemic AA amyloidosis. He had no symptoms to suggest an underlying chronic inflammatory condition but had CRP 130 mg/L and SAA 474 mg/L. In an attempt to identify the source of his inflammatory response, he underwent a contrast-enhanced whole-body computed tomography scan, which revealed a necrotising mass lesion in the right kidney consistent with a renal cell carcinoma. It also showed non-mechanical obstruction of the small bowel and, immediately post-imaging, the patient developed intractable vomiting followed by oliguric renal failure requiring haemodialysis. Despite his renal and gut failure, he underwent right radical nephrectomy without further complications. Histology showed complete resection of a clear cell renal cell carcinoma and renal amyloid deposits. Post-surgery, his acute-phase response decreased to normal, consistent with the renal cell carcinoma acting as the inflammatory stimulus. Although he remains dialysis dependent, his gut function improved and he has regained both normal weight and serum albumin. Our case demonstrates partial resolution of AA amyloidosis with removal of the inflammatory source.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–71.

    Article  CAS  PubMed  Google Scholar 

  2. Pras M, Franklin EC, Shibolet S, Frangione B. Amyloidosis associated with renal cell carcinoma of the AA type. Am J Med. 1982;73:426–8. PMID 7124769.

    Article  CAS  PubMed  Google Scholar 

  3. Jaakkola H, Törnroth T, Groop PH, Honkanen E. Renal failure and nephrotic syndrome associated with gastrointestinal stromal tumour (GIST)—a rare cause of AA amyloidosis. Nephrol Dial Transplant. 2001;16:1517–8.

    Article  CAS  PubMed  Google Scholar 

  4. Agha I, Mahoney R, Beardslee M, Liapis H, Cowart RG, Juknevicius I. Systemic amyloidosis associated with pleomorphic sarcoma of the spleen and remission of nephrotic syndrome after removal of the tumor. Am J Kidney Dis. 2002;40:411–41.

    Article  PubMed  Google Scholar 

  5. Mata M, Lohr T, Lakshminarayanan M, Lo KH, Prabhakar U. Centocor, Inc., Malvern, PA. Serum amyloid A (SAA), C-reactive protein (CRP) and IL-6 as prognostic indicators in renal cell carcinoma and prostate cancer. J Clin Oncol. 2004;22(14S):9711.

    Google Scholar 

  6. Wood SL, Rogers M, Cairns DA, Paul A, Thompson D, Vasudev NS, et al. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer. 2010;103(1):101–11. Epub 2010 Jun 8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Berger L, Sinkoff MW. Systemic manifestations of hypernephroma review of 273 cases. Am J Med. 1957;22:791–6.

    Article  CAS  PubMed  Google Scholar 

  8. Dictor M, Hasserius R. Systemic amyloidosis and non-hematologic malignancy in a large autopsy series. Acta Pathol Microbiol Scand A. 1981;89(6):411–6.

    CAS  PubMed  Google Scholar 

  9. Lavie G, Zucker-Franklin D, Franklin EC. Degradation of serum amyloid A protein by surface-associated enzymes of human blood monocytes. J Exp Med. 1978;418:1020–31.

    Article  CAS  PubMed  Google Scholar 

  10. Westermark GT, Sletten K, Grubb A, Westermark P. AA-amyloidosis. Tissue component-specific association of various protein AA subspecies and evidence of a fourth SAA gene product. Am J Pathol. 1990;137(2):377–83. PMID 2386201.

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Azzopardi JG, Lehner T. Systemic amyloidosis and malignant disease. J Clin Pathol. 1966;19(6):539–48.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Miki S, Iwano M, Miki Y, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989;250:607–10.

    Article  CAS  PubMed  Google Scholar 

  13. Rossi J-F, Négrier S, James ND, et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 2010;103:1154–62. doi:10.1038/sj.bjc.6605872.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore). 1991;70:246–56.

    Article  CAS  Google Scholar 

  15. Tanaka F, Migita K, Honda S, et al. Clinical outcome and survival of secondary (AA) amyloidosis. Clin Exp Rheumatol. 2003;21:343.

    CAS  PubMed  Google Scholar 

  16. Falck HM, Maury CP, Teppo AM, Wegelius O. Correlation of persistently high serum amyloid A protein and C-reactive protein concentrations with rapid progression of secondary amyloidosis. Br Med J (Clin Res Ed). 1983;286:1391.

    Article  CAS  Google Scholar 

  17. Lovat LB, Madhoo S, Pepys MB, Hawkins PN. Long-term survival in systemic amyloid A amyloidosis complicating Crohn’s disease. Gastroenterology. 1997;112:1362–5.

    Article  CAS  PubMed  Google Scholar 

  18. Waldenström H. On the formation and disappearance of amyloid in man. Acta Chir Scand. 1928;63:479–530.

    Google Scholar 

  19. Shimojima Y, Takei Y, Tazawa K, et al. Histopathological regression of systemic AA amyloidosis after surgical treatment of a localized Castleman’s disease. Amyloid. 2006;13:184–6.

    Article  PubMed  Google Scholar 

  20. Ortiz-Santamaría V, Olivé A, Valls-Roc M, Tena X. Treatment of AA amyloid with chlorambucil. Rheumatology (Oxford). 2002;41:833.

    Article  Google Scholar 

  21. Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Shono M, Baba S. Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol. 2003;22:371–5.

    Article  PubMed  Google Scholar 

  22. Mpofu S, Teh LS, Smith PJ, Moots RJ, Hawkins PN. Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology (Oxford). 2003;42:362–6.

    Article  CAS  Google Scholar 

  23. Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis; a 10–21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol. 1993;20:2051–7.

    CAS  PubMed  Google Scholar 

  24. Uda H, Yokota A, Kobayashi K, et al. Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol. 2006;33(8):1482–7. PMID 16881107.

    PubMed  Google Scholar 

Download references

Conflict of interest

We do not declare any conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Adarsh Babu.

About this article

Cite this article

Babu, A., Lachmann, H., Pickett, T. et al. Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literature. CEN Case Rep 3, 68–74 (2014). https://doi.org/10.1007/s13730-013-0088-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13730-013-0088-8

Keywords

Navigation